前沿生物:2027年计划推动1-2款小核酸产品完成IND申报

证券日报
Feb 25

证券日报网2月25日讯 ,前沿生物在接受调研者提问时表示,2026年及未来两年,公司将围绕现有业务板块与核心管线,推进多项研发里程碑,同时夯实长期发展基础。一是高端仿制药领域,两款分别面向美国、中国市场的产品,计划于未来两年内获批上市,为公司带来现金流支撑;二是HIV领域,持续推进差异化产品研发,力争推出1款新的创新药品种;三是小核酸领域,核心推进已公开的FB7013、FB7011、FB7023、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10